{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:23:00Z","timestamp":1777540980891,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012895","name":"Zoetis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.bmcl.2019.126624","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T01:55:36Z","timestamp":1565920536000},"page":"126624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Type 2 inhibitor leads of human tropomyosin receptor kinase (hTrkA)"],"prefix":"10.1016","volume":"29","author":[{"given":"Govindan","family":"Subramanian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott J.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Roush","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Zachary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Javens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gonzales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2019.126624_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-536-7_1","article-title":"The neurotrophin family of neurotrophic factors: an overview","volume":"846","author":"Skaper","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.bmcl.2019.126624_b0010","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","article-title":"The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification","volume":"9","author":"Hanks","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.bmcl.2019.126624_b0015","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1146\/annurev.biochem.72.121801.161629","article-title":"Trk receptors: roles in neuronal signal transduction","volume":"72","author":"Huang","year":"2003","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.bmcl.2019.126624_b0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","article-title":"TRKing down an old oncogene in a new era of targeted therapy","volume":"5","author":"Vaishnavi","year":"2015","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.bmcl.2019.126624_b0025","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1517\/13543770902721261","article-title":"Trk kinase inhibitors as new treatments for cancer and pain","volume":"19","author":"Wang","year":"2009","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmcl.2019.126624_b0030","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/papr.12342","article-title":"NGF\/TrkA signaling as a therapeutic target for pain","volume":"16","author":"Hirose","year":"2016","journal-title":"Pain Prac"},{"key":"10.1016\/j.bmcl.2019.126624_b0035","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.tips.2005.12.001","article-title":"Novel class of pain drugs based on antagonism of NGF","volume":"27","author":"Hefti","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bmcl.2019.126624_b0040","first-page":"373","article-title":"Anti-nerve growth factor in pain management: current evidence","volume":"6","author":"Chang","year":"2016","journal-title":"J Pain Res"},{"key":"10.1016\/j.bmcl.2019.126624_b0045","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s40265-017-0781-6","article-title":"Nerve growth factor antagonists: is the future of monoclonal antibodies becoming clearer?","volume":"77","author":"Bannwarth","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bmcl.2019.126624_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2131\/jts.43.1","article-title":"Development of pain therapies targeting nerve growth factor signal transduction and the strategies used to resolve safety issues","volume":"43","author":"B\u00e9langer","year":"2018","journal-title":"J Toxicol Sci"},{"key":"10.1016\/j.bmcl.2019.126624_b0055","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1021\/acs.jmedchem.8b01092","article-title":"Insights into current tropomyosin receptor kinase (TRK) inhibitors: development and clinical application","volume":"62","author":"Yan","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126624_b0060","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","article-title":"Larotrectinib: First global approval","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.bmcl.2019.126624_b0065","doi-asserted-by":"crossref","first-page":"E105","DOI":"10.3390\/cancers10040105","article-title":"Inhibiting TRK proteins in clinical cancer therapy","volume":"10","author":"Lange","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.bmcl.2019.126624_b0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmcl.2019.126624_b0075","unstructured":"Zhao Z, Bourne PE. Overview of current type I\/II kinase inhibitors. arXiv:1811.09718 [q-bio.MN]."},{"key":"10.1016\/j.bmcl.2019.126624_b0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmcl.2019.126624_b0085","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.bmcl.2019.126624_b0090","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","volume":"114","author":"Zarrinkar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2019.126624_b0095","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1158\/1078-0432.CCR-13-1610","article-title":"Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies","volume":"20","author":"Lovly","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmcl.2019.126624_b0100","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2014.104","article-title":"Acquired resistance to TKIs in solid tumours: learning from lung cancer","volume":"11","author":"Camidge","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmcl.2019.126624_b0105","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmcl.2019.126624_b0110","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.bmcl.2019.126624_b0115","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug","volume":"1","author":"Capdeville","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2019.126624_b0120","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/cb500129t","article-title":"Exploration of Type II binding mode: a privileged approach for kinase inhibitor focused drug discovery?","volume":"9","author":"Zhao","year":"2014","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmcl.2019.126624_b0125","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.bmcl.2019.126624_b0130","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/ml200261d","article-title":"Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models","volume":"3","author":"Albaugh","year":"2012","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2019.126624_b0135","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.1021\/jm5006429","article-title":"Maximizing diversity from a kinase screen: identification of novel and selective pan-Trk inhibitors for chronic pain","volume":"57","author":"Stachel","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126624_b0140","doi-asserted-by":"crossref","first-page":"10084","DOI":"10.1021\/acs.jmedchem.6b00850","article-title":"The discovery of a potent, selective, and peripherally restricted pan-Trk inhibitor (PF-06273340) for the treatment of pain","volume":"59","author":"Skerratt","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126624_b0145","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1535-7163.MCT-17-1180","article-title":"Selective TRK inhibitor CH7057288 against TRK fusion-driven cancer","volume":"17","author":"Tanaka","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmcl.2019.126624_b0150","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1021\/acs.jmedchem.8b00633","article-title":"Discovery of potent, selective, and peripherally restricted pan-Trk kinase inhibitors for the treatment of pain","volume":"61","author":"Bagal","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126624_b0155","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3762\/bjoc.12.267","article-title":"Computational methods in drug discovery","volume":"12","author":"Leelananda","year":"2016","journal-title":"Beilstein J Org Chem"},{"key":"10.1016\/j.bmcl.2019.126624_b0160","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1021\/jm0603365","article-title":"Comparison of shape-matching and docking as virtual screening tools","volume":"50","author":"Hawkins","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126624_b0165","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/ci3001277","article-title":"ZINC: A free tool to discover chemistry for biology","volume":"52","author":"Irwin","year":"2012","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmcl.2019.126624_b0170","article-title":"Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors","author":"Brandhuber","year":"2014","journal-title":"PCT Int Appl"},{"key":"10.1016\/j.bmcl.2019.126624_b0175","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1021\/acschembio.9b00126","article-title":"Deciphering the allosteric binding mechanism of the human tropomyosin receptor kinase A (hTrkA) inhibitors","volume":"14","author":"Subramanian","year":"2019","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmcl.2019.126624_b0180","doi-asserted-by":"crossref","first-page":"D365","DOI":"10.1093\/nar\/gkv1082","article-title":"KLIFS: a structural kinase-ligand interaction database","volume":"44","author":"Kooistra","year":"2016","journal-title":"Nuc Acids Res"},{"key":"10.1016\/j.bmcl.2019.126624_b0185","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm400378w","volume":"57","author":"Van Linden","year":"2014","journal-title":"J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19305542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19305542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:31:40Z","timestamp":1760772700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X19305542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":37,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0960894X19305542"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.126624","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type 2 inhibitor leads of human tropomyosin receptor kinase (hTrkA)","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.126624","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"126624"}}